| 000 | 01728 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515063324.0 | ||
| 264 | 0 | _c20070509 | |
| 008 | 200705s 0 0 eng d | ||
| 022 | _a1077-4114 | ||
| 024 | 7 |
_a10.1097/MPH.0b013e3180437ded _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aThomas, Neal J | |
| 245 | 0 | 0 |
_aPalivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision analysis model. _h[electronic resource] |
| 260 |
_bJournal of pediatric hematology/oncology _cApr 2007 |
||
| 300 |
_a227-32 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntiviral Agents _xadverse effects |
| 650 | 0 | 4 | _aBone Marrow Transplantation |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aDecision Support Techniques |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunocompromised Host |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aPalivizumab |
| 650 | 0 | 4 |
_aRespiratory Syncytial Virus Infections _xmortality |
| 650 | 0 | 4 | _aRespiratory Syncytial Virus, Human |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aHollenbeak, Christopher S | |
| 700 | 1 | _aCeneviva, Gary D | |
| 700 | 1 | _aGeskey, Joseph M | |
| 700 | 1 | _aYoung, Mark J | |
| 773 | 0 |
_tJournal of pediatric hematology/oncology _gvol. 29 _gno. 4 _gp. 227-32 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/MPH.0b013e3180437ded _zAvailable from publisher's website |
| 999 |
_c16966311 _d16966311 |
||